Study on the targeting chemotherapy using paclitaxel-implants administered subcutaneously against lymph node metastasis of H22 hepatoma carcinoma cell

WANG Xin-chao,FAN Jian,GAO Nai-rong,MIAO Yu-shan,ZHOU Wei
DOI: https://doi.org/10.3969/j.issn.1671-6264.2008.01.010
2008-01-01
Abstract:Objectives To investigate the therapeutic effect of paclitaxel and paclitaxel-implants on lymph node metastasis of H22 Hepatoma carcinoma cell.Methods The experimental mice were divided into four groups randomly,group A:no treatment;group B:control implants;group C:paclitaxel;group D:paclitaxel-implants.All mice were sacrificed on day 12 after the treatment,half of the left inguinal lymph nodes were then weighed and fixed in 10% formalin for histologic examination,the rest were minced under aseptic conditions and transferred intraperitoneally to normal recipient mice for the estimation of the mean survival time of tumor recipients.Results The quality of left inguinal lymph nodes was(96.9±16.4) mg in group A,(95.4±13.6) mg in group B,(78.4±14.2) mg in group C and(32.3±9.40) mg in group D;the mean survival time of tumor recipients was 15 d in group A,15.5 d in group B,23.5 d in group C and 28 d in group D.Conclusion Subcutaneous implantation of paclitaxel-implants is effective for the treatment of lymph node metastasis in mice for their high lymphatic uptakes and sustained release.
What problem does this paper attempt to address?